{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001001233","name":"SANGAMO THERAPEUTICS, INC","summary":"Sangamo Therapeutics is a genomic medicine company focused on serious neurological diseases using zinc finger epigenetic regulators and engineered AAV capsids. Key programs include ST-503 (Phase 1/2 for small fiber neuropathy), ST-506 (prion disease), isaralgagene civaparvovec (Fabry disease, BLA rolling submission initiated December 2025), and giroctocogene fitelparvovec (hemophilia A, rights regained from Pfizer April 2025). Collaborators include Genentech, Astellas, Alexion, Eli Lilly, and Takeda.","people":[],"products":[{"name":"ST-503","type":"platform","description":"Investigational epigenetic regulator using ZFR targeting SCN9A gene for chronic neuropathic pain due to small fiber neuropathy; Phase 1/2 STAND study ongoing."},{"name":"ST-506","type":"platform","description":"Investigational epigenetic regulator targeting PRNP gene for prion disease, delivered via STAC-BBB neurotropic AAV capsid; CTA-enabling activities underway."},{"name":"Isaralgagene civaparvovec (ST-920)","type":"platform","description":"Wholly owned gene therapy for Fabry disease; completed Phase 1/2 STAAR study; BLA rolling submission initiated December 2025."},{"name":"Giroctocogene fitelparvovec (SB-525)","type":"platform","description":"Gene therapy for moderately severe to severe hemophilia A; development rights regained from Pfizer in April 2025; seeking new collaboration partner."},{"name":"STAC-BBB","type":"platform","description":"Proprietary engineered neurotropic AAV capsid variant that crosses the blood-brain barrier via IV administration; demonstrated efficacy in NHPs and mice."},{"name":"SIFTER","type":"platform","description":"Proprietary AAV capsid engineering platform for engineering capsids with improved CNS transduction for IV and CSF administration."},{"name":"MINT (Modular Integrase)","type":"platform","description":"Next-generation protein-guided genome editing platform designed to integrate large DNA sequences into the genome for treating patients with unique mutations."}],"partnerships":[{"partner_name":"Genentech, Inc. (Roche Group)","partnership_type":"licensing","description":"Collaboration and license arrangement for preclinical candidates in tauopathies and other neurology targets; licensed STAC-BBB capsid.","start_date":null},{"partner_name":"Astellas Gene Therapies, Inc.","partnership_type":"licensing","description":"Collaboration and license arrangement for preclinical neurology candidates; licensed STAC-BBB capsid.","start_date":null},{"partner_name":"Alexion Pharmaceuticals, Inc.","partnership_type":"licensing","description":"Collaboration and license arrangement for undisclosed neurology targets.","start_date":null},{"partner_name":"Eli Lilly and Company","partnership_type":"licensing","description":"Collaboration and license arrangement for neurology targets; licensed STAC-BBB capsid.","start_date":null},{"partner_name":"Takeda Pharmaceutical Company Limited","partnership_type":"licensing","description":"Collaboration and license arrangement for ALS and other neurology targets.","start_date":null},{"partner_name":"Pfizer Inc.","partnership_type":"development","description":"Co-developed giroctocogene fitelparvovec for hemophilia A; Sangamo regained development and commercialization rights in April 2025.","start_date":null}],"affiliations":[],"origin":{"leaf":"d09f4072ac60e0ab10ae1321bf1fdea93341412bbfbb2252f651d7919526b35a","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"ba7aa2fdf20f760a20a50a1d30d5f12e13c8250537b2a817c099b7962d4b213c","parent":"260830f88a155219312fc056b4152a9fbd97fe72374d2bee80d1c487ef7a5701","source":"0001628280-26-022029","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":1,"hourly_limit":500,"remaining":499,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}